Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/175264
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrat Aparicio, Aleix-
dc.contributor.authorSchettini, Francesco-
dc.contributor.authorChic Ruché, Núria-
dc.contributor.authorBrasó Maristany, Fara-
dc.contributor.authorParé, Laia-
dc.contributor.authorPascual, Tomás-
dc.contributor.authorConte, Benedetta-
dc.contributor.authorMartínez Sáez, Olga-
dc.contributor.authorAdamo, Barbara-
dc.contributor.authorVidal Losada, Maria Jesús-
dc.contributor.authorFernández Martínez, Aranzazu-
dc.contributor.authorGonzález Farré, Blanca-
dc.contributor.authorSanfeliu, Esther-
dc.contributor.authorCejalvo Andújar, Juan Miguel-
dc.contributor.authorPerrone, Giuseppe-
dc.contributor.authorSabarese, Giovanna-
dc.contributor.authorZalfa, Francesca-
dc.contributor.authorVillagrasa, Patricia-
dc.contributor.authorGavilá, Joaquín-
dc.contributor.authorBarrios, Carlos H.-
dc.contributor.authorLluch, Ana-
dc.contributor.authorMartín, Miguel-
dc.contributor.authorPlacido, Sabino De-
dc.contributor.authorBarnadas, Esther-
dc.contributor.authorLocci, Mariavittoria-
dc.contributor.authorPeg, Vicente-
dc.contributor.authorFasan, Roberta-
dc.date.accessioned2021-03-17T15:54:35Z-
dc.date.available2021-03-17T15:54:35Z-
dc.date.issued2021-01-04-
dc.identifier.urihttp://hdl.handle.net/2445/175264-
dc.description.abstractNovel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Nature-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41523-020-00208-2-
dc.relation.ispartofNpj Breast Cancer, 2021, vol. 7-
dc.relation.urihttps://doi.org/10.1038/s41523-020-00208-2-
dc.rightscc-by (c) Prat, Aleix et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationCàncer de mama-
dc.subject.classificationExpressió gènica-
dc.subject.otherBreast cancer-
dc.subject.otherGene expression-
dc.titleClinical, pathological and PAM50 gene expression features of HER2-low breast cancer-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec706374-
dc.date.updated2021-03-17T15:54:36Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/847912/EU//RESCUER-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33397968-
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
706374.pdf1.69 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons